VENTAIRE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VENTAIRE (VENTAIRE).
Ventaire (broxaterol) is a selective beta-2 adrenergic receptor agonist that stimulates adenyl cyclase, increasing intracellular cyclic AMP (cAMP) in bronchial smooth muscle, leading to bronchodilation.
| Metabolism | Primarily hepatic via conjugation (glucuronidation and sulfation); minor CYP450 involvement. |
| Excretion | Primarily renal excretion of unchanged drug (70-80%) and metabolites (10-15%); biliary/fecal excretion accounts for <5%. |
| Half-life | Terminal elimination half-life is 8-12 hours; clinical context: steady-state reached in 2-3 days, trough levels predict efficacy. |
| Protein binding | 95% bound to serum albumin. |
| Volume of Distribution | Vd 0.3-0.5 L/kg; indicates primarily extracellular fluid distribution, limited tissue penetration. |
| Bioavailability | Oral: 75% (low first-pass metabolism); Intravenous: 100%. |
| Onset of Action | Intravenous: 5-10 minutes; Oral: 30-60 minutes. |
| Duration of Action | 8-12 hours; clinical notes: dosing interval typically q12h for sustained effect. |
| Molecular Weight | 367.44 Da (bambuterol hydrochloride); free base 330.4 Da |
1-2 inhalations (25-50 mcg salmeterol and 100-200 mcg fluticasone) twice daily via inhalation aerosol.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, use with caution and monitor for systemic corticosteroid effects. |
| Liver impairment | Child-Pugh class A: no adjustment. Child-Pugh class B: reduce to 1 inhalation twice daily of lowest strength. Child-Pugh class C: contraindicated. |
| Pediatric use | Age ≥12 years: 1 inhalation (25 mcg salmeterol/100 mcg fluticasone) twice daily. Maximum: 1 inhalation (25/250) twice daily. Age 4-11 years: 1 inhalation (25/100) twice daily. |
| Geriatric use | Initiate at lowest strength (25/100) twice daily; monitor for adverse effects and tolerance; no specific dose adjustment except based on hepatic/renal function. |
| 1st trimester | Ventaire (bambuterol) is a prodrug of terbutaline. Terbutaline is FDA Pregnancy Category C; animal studies show adverse effects but human data limited. Use only if benefit outweighs risk; avoid during first trimester due to potential teratogenicity. |
| 2nd trimester | Limited human data; animal studies show no consistent teratogenic effects. However, terbutaline may inhibit uterine contractions; use with caution if preterm labor risk. |
| 3rd trimester | Terbutaline can delay onset of labor and has been associated with maternal tachycardia, pulmonary edema, and fetal tachycardia. Avoid use near term unless clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for VENTAIRE (VENTAIRE).
| Placental transfer | Terbutaline crosses the placenta; umbilical cord serum levels are approximately 50% of maternal serum levels. Bambuterol itself is a prodrug, but active metabolite terbutaline crosses. |
| Breastfeeding |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to bambuterol or terbutalineCardiac arrhythmias, especially tachyarrhythmiasHypertrophic obstructive cardiomyopathySevere ischemic heart disease
| Precautions | Paradoxical bronchospasm, Cardiovascular effects (tachycardia, arrhythmias), Hypokalemia, Hyperglycemia, Immediate hypersensitivity reactions |
| Food/Dietary | No significant food interactions reported. Avoid grapefruit juice if taking concurrent oral corticosteroids, but not required for inhaled form. |
| Clinical Pearls |
Loading safety data…
| Ventaire (bambuterol) is metabolized to terbutaline, which is excreted into breast milk in small amounts (estimated relative infant dose <2%). No reports of adverse effects in infants. Use with caution; monitor infant for signs of sympathomimetic stimulation. |
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Category X: Contraindicated in pregnancy. First trimester exposure associated with major congenital malformations including cardiovascular and central nervous system defects. Second and third trimester use linked to fetal growth restriction, oligohydramnios, and neonatal renal impairment. |
| Fetal Monitoring | Monitor fetal growth and amniotic fluid volume via ultrasound every 2-4 weeks. Assess fetal heart rate patterns. In neonates, monitor renal function and blood pressure for 48 hours post-delivery. |
| Fertility Effects | May impair fertility in females by disrupting ovarian function based on animal studies. Reversible upon discontinuation. |
| VENTAIRE (fluticasone propionate/salmeterol) is an inhaled corticosteroid/long-acting beta-agonist combination for maintenance asthma or COPD. Advise patients to rinse mouth after use to prevent oral candidiasis. Do not use for acute bronchospasm. Monitor for adrenal insufficiency during stress or withdrawal. |
| Patient Advice | Use VENTAIRE exactly as prescribed; do not use more often than directed. · Rinse your mouth with water after each use to prevent thrush. · Do not stop using VENTAIRE suddenly; consult your doctor before stopping. · Keep a rescue inhaler (e.g., albuterol) for sudden breathing problems. · Call your doctor if you need more rescue inhaler puffs than usual. |